ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1304

Uveitis Occurrence in Early Inflammatory Back Pain: Five Years Data from a Prospective French Nationwide Cohort

Daniel Wendling1, Clement Prati2, Thierry Lequerre3, Corinne Miceli-Richard4, Maxime Dougados5, Anna Molto6 and Xavier Guillot7, 1CHU Besançon, department of rheumatology, Besancon, France, 2Rheumatology, University Teaching Hospital, Besançon, France, 3Rheumatology, University Teaching Hospital, Rouen, France, 4Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 5Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, 6Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, 7CHU Reunion, Saint Denis, Reunion

Meeting: ACR Convergence 2020

Keywords: , ,

Session Information

Date: Sunday, November 8, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Uveitis is the most frequent extra rheumatological manifestation in axial Spondyloarthritis (SpA). DESIR is a prospective multicenter cohort of patients with early inflammatory back pain suggestive of SpA. We reported previously a 8.5% baseline prevalence of uveitis for the patients included in the cohort; this history of uveitis at the first visit of the cohort was associated with inflammatory bowel disease (IBD) and preceding infection (1).

The aim of the study was to evaluate the prevalence and incidence of uveitis over the first five years of prospective follow-up of the cohort, and to evaluate its associated factors.

Methods: DESIR is a prospective observational cohort of patients with recent onset inflammatory back pain (more than 3 months, less than 3 years), suggestive of axial SpA, All available factors in the database were compared between patients with and without uveitis at 5 years, by uni and then multivariate analysis. Baseline factors associated with new cases of uveitis occurrence over the 5 years were also analyzed. Significance: p less than 0.05.

Results: After 5 years, 91 patients (out of 480 with complete follow-up) had at least one uveitis episode, giving an estimated prevalence of 18.9% [95%CI : 15.4-22.4]. In multivariate analysis, uveitis was associated with dactylitis (OR 2.92 [2.06 – 4.14] ; p=0.002**), ESR  > 7mm (median value) (OR 2.19 [1.57 – 3.06] ; p=0.018*).

New incident uveitis occurred in 31 cases over 5 years, giving an estimated incidence rate of 1.29 / 100 patient-years [0.84 – 1.74]. New incidence of uveitis was associated in multivariate analysis with the following baseline factors: diagnosis of SpA (OR 9.65 [3.21 – 28.96] ; p=0.039*), total sacro iliac MRI inflammatory SPARCC score (central reading) over median (OR 3.98 [2.26 – 7] ; p=0.015*), dactylitis (OR 4.7 [2.65 – 8.36] ; p=0.007**), syndesmophyte score over median (central reading) (OR 0.22 [0.1 – 0.45] ; p=0.039*).

No significant association was found with HLA-B27, cs or b DMARDs, BASDAI, ASDAS, BASFI.

Conclusion: Five-years data of the DESIR cohort allowed an estimation of incidence rate of uveitis of 1.3/100p-y; over five years, uveitis was associated with dactylitis, biologic and sacro iliac MRI inflammation.

 

(1) Wendling D, et al. Arthritis Care Res (Hoboken). 2012 Jul;64(7):1089-93.

Disclosure: D. Wendling, None; C. Prati, None; T. Lequerre, None; C. Miceli-Richard, AbbVie, 2, 5, Bristol-Myers Squibb, 2, 8, Novartis, 2, 5, MSD, 2, Pfizer, 2, 5, 8, UCB, 2, 5, Biogen, 2, Wyeth, 2, 8, Schering-Plough, 8, Roche, 5, 8, Merck, 2, 5, 8, Abbott, 8; M. Dougados, Pfizer, 1, 2, Abbvie, 1, 2, UCB, 1, 2, Merck, 1, 2, Lilly, 1, 2, BMS, 1, 2, Roche, 1, 2, Novartis, 1, 2; A. Molto, ABBVIE, 5, BMS, 5, 8, LILLY, 5, NOVARTIS, 5, 8, UCB, 5, 8, GILEAD, 5; X. Guillot, None.

To cite this abstract in AMA style:

Wendling D, Prati C, Lequerre T, Miceli-Richard C, Dougados M, Molto A, Guillot X. Uveitis Occurrence in Early Inflammatory Back Pain: Five Years Data from a Prospective French Nationwide Cohort [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/uveitis-occurrence-in-early-inflammatory-back-pain-five-years-data-from-a-prospective-french-nationwide-cohort/. Accessed .

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/uveitis-occurrence-in-early-inflammatory-back-pain-five-years-data-from-a-prospective-french-nationwide-cohort/